journal article·2019-12-04Open access

Determination and pharmacokinetic study of isothiouronium-modified pyrimidine-substituted curcumin analog (1G), a novel antitumor agent, in rat plasma by liquid chromatography–tandem mass spectrometry

Jialin Sun, Jinpeng Wang, Lin Ma, Tao Jiang, Xiao Li, Qie Guo, Xiangpeng Li, Zhongguo Sui

Abstract

1G, a novel derivative of curcumin, exhibits promising anticancer activities in various cancer cell lines. To support its further pharmacological studies, a liquid chromatography-tandem mass spectrometry method was developed and validated in accordance with FDA's Guidance. After extraction by protein precipitation, analytes were separated by a 4.5 min gradient elution (water/0.1% formic acid and methanol) on a reverse-phase C18 column at 40 °C. The multiple reaction monitoring mode was used for quantification on a triple quadrupole mass spectrometer with positive ionization. The assay was linear over the concentration range of 5-1000 ng/mL with a correlation coefficient (r) greater than 0.99. Values of intra- and inter-day precision and accuracy were satisfactory, i.e. <10.1% for precision and within ± 14.5% for accuracy. No obvious matrix effect was observed. Recovery of the analyte was higher than 95.3%. 1G was stable during the whole analytic process. The validated method was successfully applied to the pharmacokinetic study of 1G after intravenous and intraperitoneal administration in rats. Favorable pharmacokinetic profiles were demonstrated, including good abdominal absorption (F = 62.58%), moderate clearance and high extravascular distribution. Results indicated that as a novel antitumor agent, 1G exhibited acceptable pharmacokinetic properties for further in vivo pharmacologic evaluation.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Curcumin's Biomedical Applications · Synthesis and bioactivity of alkaloids · Drug Transport and Resistance Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy, the Affiliated Hospital of Qingdao University

Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China

Funding

the Beijing Medical and Health Foundation · the Affiliated Hospital of Qingdao University

References (28)

Show source-provided references
1. 10.1089/neu.2014.352010.1089/neu.2014.3520 ↗
2. 10.1208/s12249-017-0832-z10.1208/s12249-017-0832-z ↗
3. 10.3390/molecules2005918310.3390/molecules20059183 ↗
4. 10.1080/13880209.2017.129783810.1080/13880209.2017.1297838 ↗
5. 10.2147/IJN.S6275610.2147/IJN.S62756 ↗
6. 10.3390/ijms1905136110.3390/ijms19051361 ↗
7. Marslin G, Sarmento BF, Franklin G, et al. Curcumin encapsulated into methoxy poly(ethylene glycol) poly(epsilon-caprolactone) nanoparticles increases cellular uptake and neuroprotective effect in glioma cells. Planta Med. 2017;83:434–444.
8. 10.1021/acs.molpharmaceut.5b0061110.1021/acs.molpharmaceut.5b00611 ↗
9. 10.1021/acsami.7b0286310.1021/acsami.7b02863 ↗
10. Zheng BZ, Liu TD, Chen G, et al. The effect of curcumin on cell adhesion of human esophageal cancer cell. Eur Rev Med Pharmacol Sci. 2018;22:551–560.
11. Huang F, Yao Y, Wu J, et al. Curcumin inhibits gastric cancer-derived mesenchymal stem cells mediated angiogenesis by regulating NF-kappaB/VEGF signaling. Am J Transl Res. 2017;9:5538–5547.
12. 10.1016/j.jhep.2015.04.01810.1016/j.jhep.2015.04.018 ↗
13. 10.1111/1759-7714.1246710.1111/1759-7714.12467 ↗
14. 10.1038/srep2005110.1038/srep20051 ↗
15. 10.1021/mp700113r10.1021/mp700113r ↗
16. Carolina Alves R, Perosa Fernandes R, Fonseca-Santos B, et al. A critical review of the properties and analytical methods for the determination of curcumin in biological and pharmaceutical matrices. Crit Rev Anal Chem. 2018.
17. 10.1039/C7FO01814B10.1039/C7FO01814B ↗
18. 10.3109/21691401.2016.114673610.3109/21691401.2016.1146736 ↗
19. 10.1016/j.ejps.2015.11.01010.1016/j.ejps.2015.11.010 ↗
20. 10.1080/21691401.2017.133702010.1080/21691401.2017.1337020 ↗
21. 10.1016/j.bmc.2013.06.05310.1016/j.bmc.2013.06.053 ↗
22. 10.1089/ars.2014.607410.1089/ars.2014.6074 ↗
23. 10.1016/j.ejmech.2016.07.07110.1016/j.ejmech.2016.07.071 ↗
24. 10.1200/EDBK_18046010.1200/EDBK_180460 ↗
25. 10.1016/j.jpba.2015.09.00210.1016/j.jpba.2015.09.002 ↗
26. 10.1158/1078-0432.CCR-12-149910.1158/1078-0432.CCR-12-1499 ↗
27. US Food and Drug Administration CfDEaR. Guidance for Industry: Bioanalytical Method Validation; 2018. Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm070107.pdf.
28. 10.1023/A:101894361312210.1023/A:1018943613122 ↗